Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
BNZ | Ann: July 2024 Financial and Management Reports | 13/09/24 | 0 | 288 | |||
|
|||||||
BNZ | Ann: Statement of CDIs on issue - BNZ | 06/09/24 | 0 | 181 | |||
|
|||||||
BNZ | Ann: Appendix 4G | 29/08/24 | 0 | 182 | |||
|
|||||||
BNZ | Ann: Annual Report to shareholders | 29/08/24 | 0 | 257 | |||
|
|||||||
BNZ | Ann: Statement of CDIs on issue - BNZ | 05/08/24 | 0 | 240 | |||
|
|||||||
BNZ | Ann: Annual Financial Statements and MD&A for FYE 30 April 2024 | 29/07/24 | 0 | 250 | |||
|
|||||||
BNZ | something is cooking | 24/07/24 | 14 | 6.1K | |||
|
|||||||
BNZ | Ann: Statement of CDIs on issue - BNZ | 05/07/24 | 0 | 208 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |